Eduardo Yáñez

962 total citations
26 papers, 314 citations indexed

About

Eduardo Yáñez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Eduardo Yáñez has authored 26 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Obstetrics and Gynecology. Recurrent topics in Eduardo Yáñez's work include Cancer Immunotherapy and Biomarkers (13 papers), Endometrial and Cervical Cancer Treatments (8 papers) and HER2/EGFR in Cancer Research (5 papers). Eduardo Yáñez is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Endometrial and Cervical Cancer Treatments (8 papers) and HER2/EGFR in Cancer Research (5 papers). Eduardo Yáñez collaborates with scholars based in Chile, United States and France. Eduardo Yáñez's co-authors include Razi Ghori, Carlos Gomez‐Roca, Hyun Cheol Chung, Kevin Norwood, Sanjeev Gill, Corinne Maurice‐Dror, Peter Kubiak, Javier García-Corbacho, Hélène Senellart and Bristi Basu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Eduardo Yáñez

25 papers receiving 310 citations

Peers

Eduardo Yáñez
Comparison fields: 5 of 41
  • Oncology 247
  • Surgery 134
  • Pulmonary and Respiratory Medicine 106
  • Pathology and Forensic Medicine 54
  • Immunology 40
Replace L. V. Manzyuk with:
L. V. Manzyuk Russia
N. Tsavaris Greece
Benjamin Bonhomme France
И. А. Покатаев Russia
Pauline Corbaux France
Ning‐Fu Peng China
Jiaoyue Jin China
Ken Kato Japan
Peter Kubiak United States
Dalyong Kim South Korea
L. V. Manzyuk Russia View profile →
Citations per field, relative to Eduardo Yáñez
Eduardo Yáñez · 1×
Citations per year, relative to Eduardo Yáñez
Eduardo Yáñez · 1×

Countries citing papers authored by Eduardo Yáñez

Since Specialization
Citations

This map shows the geographic impact of Eduardo Yáñez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eduardo Yáñez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eduardo Yáñez more than expected).

Fields of papers citing papers by Eduardo Yáñez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eduardo Yáñez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eduardo Yáñez. The network helps show where Eduardo Yáñez may publish in the future.

Co-authorship network of co-authors of Eduardo Yáñez

This figure shows the co-authorship network connecting the top 25 collaborators of Eduardo Yáñez. A scholar is included among the top collaborators of Eduardo Yáñez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eduardo Yáñez. Eduardo Yáñez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) ± anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830.
2025 ·Journal of Clinical Oncology ·Jung‐Yun Lee, Carolina Ibáñez, Mariusz Bidziński, Ora Rosengarten, Emad Matanes, (unknown), Toon Van Gorp, Marta Gil-Martín, (unknown), Chien‐Hsing Lu, Eduardo Yáñez, (unknown), Christof Vulsteke, Alejandro Acevedo, Eugenia Girda, Ana Oaknin, Steven M. Townson, Yiwei Zhang, Julie Kobie, Domenica Lorusso
1
2
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
2024 ·Cancer ·Hyun Cheol Chung, Esma Saâda-Bouzid, Federico Longo, Eduardo Yáñez, Seock‐Ah Im, Eduardo Castañón, Danielle Desautels, Donna M. Graham, Javier García-Corbacho, Juanita Lopez, Corina E. Dutcus, Chinyere E. Okpara, Razi Ghori, Fan Jin, Roman Groisberg, (unknown)
4
3
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
2024 ·Annals of Oncology ·(unknown), Nicoletta Colombo, Coraline Dubot, (unknown), Kazuki Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, (unknown), Ka Wan Li, (unknown), (unknown), Krishnansu S. Tewari, (unknown)
9
4
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
2024 ·Gynecologic Oncology ·Antonio González-Martı́n, Hyun Cheol Chung, Esma Saâda-Bouzid, Eduardo Yáñez, Hélène Senellart, Philippe A. Cassier, Bristi Basu, Bradley R. Corr, Eugenia Girda, Corina E. Dutcus, Chinyere E. Okpara, Razi Ghori, Fan Jin, Roman Groisberg, Zarnie Lwin
8
5
#67 Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826
2023 ·Domenica Lorusso, Nicoletta Colombo, Bradley J. Monk, Coraline Dubot, (unknown), Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, (unknown), Kan Li, Sarper Toker, Cumhur Tekin, Krishnansu S. Tewari
3
6
#1121 KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
2023 ·Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, А. В. Архипов, Cumhur Tekin, Kan Li, Stephen J. O’Keefe, Domenica Lorusso
2
7
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
2023 ·JAMA Oncology ·Krishnansu S. Tewari, Nicoletta Colombo, Bradley J. Monk, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, (unknown), Cumhur Tekin, Kan Li, Sarper Toker, Stephen J. O’Keefe, Domenica Lorusso
21
8
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
2022 ·BioDrugs ·Rubi K. Li, Eriko Tokunaga, Hryhoriy Adamchuk, Vladimir Vladimirov, Eduardo Yáñez, Keun Seok Lee, Igor Bondarenko, (unknown), Fiona Hilton, Tomofumi Ishikawa, (unknown), Oleg Lipatov
12
9
Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.
2022 ·Journal of Clinical Oncology ·Krishnansu S. Tewari, Nicoletta Colombo, Bradley J. Monk, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, (unknown), Cumhur Tekin, Kan Li, Sarper Toker, Stephen J. O’Keefe, Domenica Lorusso
9
10
FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study.
2022 ·Journal of Clinical Oncology ·Angeles Alvarez Secord, Lisa Barroilhet, Myong Cheol Lim, Sunil Gupta, (unknown), (unknown), John O. Schorge, Joyce N. Barlin, Lucy Gilbert, Devansu Tewari, Michael A. Gold, Diane Provencher, Jung‐Yun Lee, Kristin Bixel, Eduardo Yáñez, Lukáš Rob, David M. O’Malley
3
11
Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)
2022 ·Gynecologic Oncology ·Bradley J. Monk, Krishnansu Tewari, Coraline Dubot, (unknown), Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, (unknown), Cumhur Tekin, Kan Li, Allison Martin Nguyen, Matthew Monberg, Nicoletta Colombo, Domenica Lorusso
1
12
Pegathor Lymphoma, a Phase 2 Study of SAR444245 As a Monotherapy or in Combination with Pembrolizumab for the Treatment of Adults and Adolescents with Relapsed or Refractory B Cell Lymphoma
2022 ·Blood ·(unknown), Eduardo Yáñez, Christine Rojas, (unknown), (unknown), Anna Sureda, (unknown), Robin Meng, Jing Xu, Michael Streit, (unknown), Sairah Ahmed
1
13
LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
2021 ·Annals of Oncology ·Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, (unknown), Kosei Hasegawa, Ronnie Shapira‐Frommer, Krishnansu S. Tewari, Pamela Salman, Eduardo Aguayo de Hoyos, Eduardo Yáñez, (unknown), Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, (unknown), (unknown), Ka Wan Li, Stephen J. O’Keefe, B.J. Monk
4
14
Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study
2021 ·Cancer Research ·Hyun Cheol Chung, Esma Saâda-Bouzid, (unknown), Eduardo Yáñez, Seock‐Ah Im, Eduardo Castañón, Donna M. Graham, Javier García-Corbacho, Juanita Lopez, Razi Ghori, Corina E. Dutcus, Alan D. Smith, Kevin Norwood, Carlos Gomez‐Roca
9
15
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.
2021 ·Journal of Clinical Oncology ·Hyun Cheol Chung, Zarnie Lwin, Carlos Gomez‐Roca, Federico Longo, Eduardo Yáñez, (unknown), Donna M. Graham, Mark Doherty, Philippe A. Cassier, Juanita Lopez, Bristi Basu, Andrew Hendifar, Corinne Maurice‐Dror, Sanjeev Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Esma Saâda-Bouzid
4
16
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.
2021 ·Journal of Clinical Oncology ·Luis J. Villanueva-Rivera, Zarnie Lwin, Hyun Cheol Chung, Carlos Gomez‐Roca, Federico Longo, Eduardo Yáñez, Hélène Senellart, Mark Doherty, Javier García-Corbacho, Andrew Hendifar, Corinne Maurice‐Dror, Sanjeev Gill, Tae Won Kim, Daniel Heudobler, Nicolas Penel, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Donna M. Graham
49
17
Abstract P1-18-08: Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data
2020 ·Cancer Research ·Rubi K. Li, Oleg Lipatov, Hryhoriy Adamchuk, Vladimir Vladimirov, Eduardo Yáñez, (unknown), Amy Freyman, Fiona Hilton, Alexandra Thiele, (unknown)
2
18
¿Cuál es el Rol de la Cirugía en el Tratamiento de un Paciente con Cáncer de la Vesícula Biliar Estadio IIIb?
2015 ·International Journal of Morphology ·Carlos Manterola, (unknown), Eduardo Yáñez
0
19
Preoperative Chemoradiotherapy in the Treatment of Gallbladder Cancer
1999 ·The American Surgeon ·Xabier de Aretxabala, Iván Roa, L. Burgos, (unknown), Jorge Silva, Eduardo Yáñez, Juan Carlos Araya, Miguel Villaseca, (unknown), (unknown)
28
20
Model based simulation for survey planning and optimization
1999 ·(unknown), Víctor Pereyra, Alfredo Rosado-Muñoz, (unknown), (unknown), Eduardo Yáñez, (unknown)
4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. V. Manzyuk Breakdown of academic impact, for papers by N. Tsavaris Breakdown of academic impact, for papers by Benjamin Bonhomme Breakdown of academic impact, for papers by И. А. Покатаев Breakdown of academic impact, for papers by Pauline Corbaux Breakdown of academic impact, for papers by Ning‐Fu Peng Breakdown of academic impact, for papers by Jiaoyue Jin Breakdown of academic impact, for papers by Ken Kato Breakdown of academic impact, for papers by Peter Kubiak Breakdown of academic impact, for papers by Dalyong Kim
Rankless by CCL
2026